Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-26T12:44:37.428Z Has data issue: false hasContentIssue false
  • English
  • Français

Mild Cognitive Impairment and Quality of Life

Published online by Cambridge University Press:  16 April 2020

C. Mila ,
D.M. Podea  and
R.M. Chenderes
C. Mila
Affiliation:
Psychiatry, West Vasile Goldis University of Arad, Arad, Romania
D.M. Podea
Affiliation:
Psychiatry, West Vasile Goldis University of Arad, Arad, Romania
R.M. Chenderes
Affiliation:
Psychiatry, West Vasile Goldis University of Arad, Arad, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

The aim of this study is to evaluate the influence of cognitive enhancers on quality of life to patients with MCI.

Material and methods:

The study comprises a number of 40 elderly patients diagnosed with mild cognitive impairment. These patients were divided in two groups:

  • group A that comprises 20 patients diagnosed with mild cognitive impairment that were treated with piracetamum (daily dose: 1600mg),

  • group B that comprises 20 patients diagnosed with mild cognitive impairment that were treated with antioxidants Coenzima Q10 (daily dose: 15mg).

MMSE score between 28-21points is considered mild cognitive impairment. The inclusion criteria were:

  • patients over 65 years,

  • patients with mild cognitive impairment.

  • The exclusion criteria were:

  • patients with mild cognitive impairment due to major depressive disorder and schizophrenia,

  • patients with moderate and severe cognitive impairment.

  • The patients were evaluated with MMSE (Mini Mental State Evaluation) and GAF (Global Assessment of Functioning Scale) at the inclusion and after 6 months of treatment.

Results:

The average of MMSE scores in group A was 25.9 and for group B 25.5. The patients treated with nootropics have had a better outcome, cognitive performance improving with 2,6 points for group A and with 1,8 points for group B. Improvement of cognitive performance improve the quality of life of this patients, the GAF scores improving from 45.4 points to 67.3 in group A and from 44.8 points to 55.3 in group B.

Conclusions:

The patients treated with nootopics have had a better outcome regarding cognitive functions and quality of life also. Improvement of cognitive performance improve the quality of life.

Type
P02-173
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E863
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.